Novel Presentation of Terminal Ileitis Associated with Secukinumab Therapy.
Publication/Presentation Date
1-1-2021
Abstract
Inflammatory bowel disease (IBD) and psoriasis are chronic inflammatory immune-mediated diseases. The interleukin-23- (IL23-) T helper (Th)17 pathway has been implicated in their pathogenesis, with multiple biologic therapies targeting this pathway. IL-17, the main proinflammatory cytokine produced by (TH)17, has been targeted by antibodies and IL-17 receptor blockers with favorable outcomes in treating psoriasis and psoriatic arthritis. However, their role in IBD is unpredictable as studies reported worsening of IBD with agents targeting IL-17 and rare case reports with new-onset IBD. We present a case of Crohn's-like severe terminal ileitis and worsening diverticulitis complicated by intestinal perforation requiring total parenteral nutrition shortly after being started on secukinumab.
Volume
2021
First Page
5213876
Last Page
5213876
ISSN
2090-6528
Published In/Presented At
Ahmed Shaheen, A., Hader, I., & Aqel, Z. (2021). Novel Presentation of Terminal Ileitis Associated with Secukinumab Therapy. Case reports in gastrointestinal medicine, 2021, 5213876. https://doi.org/10.1155/2021/5213876
Disciplines
Diagnosis | Medicine and Health Sciences | Other Analytical, Diagnostic and Therapeutic Techniques and Equipment | Radiology
PubMedID
34621550
Department(s)
Department of Radiology and Diagnostic Medical Imaging
Document Type
Article